I am a transplant surgeon witnessing an unsettling trend: the age of my patients is decreasing, with many now in their 30s and 40s due to conditions linked to childhood obesity. This alarming reality complicates the organ transplant landscape since obesity can hinder eligibility for transplants.
Statistical evidence corroborates clinical observations: adolescents with severe obesity face up to a ninefold increase in chronic kidney disease risk in young adulthood, independent of diabetes or hypertension. In addition, childhood fatty liver disease is associated with a staggering 40-fold increase in mortality risk, posing a significant concern as it becomes a leading cause of liver transplants in young adults.
These statistics spurred my interest in obesity medicine. While facilitating organ transplants is essential, preemptive interventions are vital to alleviate the burden of organ failure.
Alarmingly, around 20% of children in the U.S. are affected by obesity, and we can't overlook the implications this statistic carries for the future.
Recently, my research team reported a staggering 310-fold rise in GLP-1 receptor agonist prescriptions for children aged 8-11 suffering from obesity since 2019. Although several drugs in this class are cleared for use in adolescents aged 12 and older, options for younger children remain unapproved.
Securing FDA approval for these medications in younger children could not only enhance insurance coverage but also bridge the accessibility gap highlighted in our study. Yet, this could encourage overprescribing for less severe cases without sufficient long-term data on growth and puberty outcomes.
When the American Academy of Pediatrics updated its obesity management guidelines incorporating GLP-1 recommendations in 2023, the public's reaction was mixed. I understand the unease this creates. The thought of children receiving injections for weight management challenges our instincts to let kids enjoy their childhood.
However, the data present a more complex picture: among over 3.5 million children ages 8-11 with obesity, only 0.6% were prescribed GLP-1 drugs. Alarmingly, a significant proportion of those who could benefit remain untreated.
Notably, the pediatricians I collaborate with are judiciously prescribing these medications for children in severe health conditions; 94% of GLP-1 recipients had severe obesity, already facing adult conditions like sleep apnea and metabolic disorders.
I empathize with concerns regarding the “medicalization” of childhood. Yet, blindly neglecting the realities of childhood obesity leads to a medicalized adult life for these children — catalyzed not by healthcare providers, but by systemic factors that foster obesity.
Today's children navigate environments that discourage physical activity and are inundated with unhealthy food options. A multifaceted approach is required to address obesity, particularly when 20% of U.S. children are affected. For too long, the focus has been on placing blame rather than identifying the systemic failures at play.
It’s crucial to reject binary thinking around this issue, such as choosing between fixing food systems and providing treatment. Such a dichotomy fosters a sense of therapeutic hopelessness. Instead, we should pursue policy changes, like taxing sugary drinks and enhancing school nutrition standards, that address root causes while also offering evidence-based care for those in need.
Transplantation is undoubtedly a lifesaving procedure, but the intense waiting periods and lifelong immunosuppression highlight the need for preventive measures. What if we could intervene at an earlier stage, mitigating the necessity for organ transplants altogether? Addressing childhood obesity is not just a medical imperative; it’s an ethical obligation to ensure these young individuals have a healthier future.
My commitment as an obesity medicine specialist allows me to engage with patients at early intervention stages rather than at critical endpoints. Treating children grappling with obesity and simultaneously advocating for systemic reforms are not just parallel endeavors; they are critical components of a holistic approach to health.
Babak J. Orandi, M.D., Ph.D, is a transplant surgeon, an obesity medicine specialist, a health services researcher, and an associate professor of surgery and medicine at NYU Langone.